Head & Neck Cancer

In some patients with head and neck cancer, those who require dental care after cancer treatment may face financial burdens because of out-of-pocket costs.

In addition to increased treatment costs, patients with head and neck cancers also experienced therapy changes during the cisplatin shortage.

A trial showed no overall survival or progression-free survival benefit from the addition of UV1 to Keytruda in patients with HNSCC.

From Patti Yasutake’s death from cancer to Olympic water polo player’s husband’s rare cancer diagnosis, here’s what’s happening in the oncology space this week.

CURE® spoke to an expert from Emory University in Atlanta about tonsil cancer, its “gold standard” treatment and potential side effects.

Patients with head and neck squamous cell carcinoma can talk to their care team about a trial evaluating petosemtamab for recurrent or metastatic disease.

Updated data has been reported evaluating efti and Keytruda in PD-L1 negative recurrent or metastatic head and neck squamous cell carcinoma.

From the lead singer of Heart’s cancer diagnosis and postponing their tour to Dick Vitale’s upcoming cancer surgery, here’s what’s going on in the cancer space this week.

The immunotherapy Opvido and reirradiation resulted in a one-year progression-free survival rate of 61.7% among certain patients with head and neck cancer.

When compared with unvaccinated patients, HPV vaccines were associated with lower rates of HPV-related cancer for people younger than 40.

A breakthrough therapy designation was granted to petosemtamab by the FDA to treat patients with recurrent or metastatic head and neck cancers.

Patients with laryngeal cancer who stopped smoking before receiving treatment had better survival outcomes, compared with patients who actively smoke.

Cancer is an emotionless assassin that can attack us and the ones we love most.

Of all the bad whatifs about cancer that creep into my ear, what if I turned them into positive whatifs?

From Jason Kelce honoring the team trainer who has been diagnosed with cancer to deaths in the sports reporting and music world, here’s what’s happening in the oncology space this week.

Treatment paradigms may soon be shifting in head and neck cancer, as recent research indicates that lower doses of chemoradiotherapy may be appropriate for some patients.

Substance use disorders, such as alcohol use disorder, were found to be more prevalent among survivors of specific cancer types, according to research.

The Food and Drug Administration gave the green light to a phase 1/2 trial of KSQ-001EX for patients with melanoma, head and neck squamous cell carcinoma and non-small cell lung cancer.

From Dick Vitale to Make-A-Wish’s Miles Scott reveal that they are cancer free, here is what’s happening in the oncology space this week.

I was diagnosed with a rare cancer in 2007, and it shaped who I am today.

Patients with metastatic or recurrent head and neck squamous cell carcinoma had durable antitumor activity, according to findings from a phase 2 trial.

The Food and Drug Administration approved Loqtorzi with and without chemotherapy for certain patients with nasopharyngeal carcinoma.

Oral microbiome “plays an important role” in patterns of oral mucositis, an after-effect experienced by nearly all patients with head and neck cancer treated with chemotherapy and radiotherapy.

As Connor McGregor honors a fan who dies from cancer and Steve Scalise reveals information about his blood cancer, this is what’s happening in the oncology space this week.

Researchers are using artificial intelligence to diagnose sarcopenia in patients with head and neck cancer.

Patients with head and neck cancer treated with dysphagia-optimized intensity-modulated radiotherapy had improved swallow function compared with those treated with standard intensity-modulated radiotherapy.

Patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy reported higher quality of life and were less likely to experience vomiting when receiving fosaprepitant every week as opposed to every three weeks.

Researchers found a difference in outcomes between head and neck cancers with high and low expression of NF-kB, which may one day lead to more personalized treatments for the disease.

We recently asked our audience of patients, survivors and caregivers about the ongoing cisplatin and carboplatin shortage. Here’s what they had to say.